Pair Name | Jervine, Decitabine | ||
Phytochemical Name | Jervine (PubChem CID: 10098 ) | ||
Anticancer drug Name | Decitabine (PubChem CID: 451668 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Jervine, Decitabine | |||
Disease Info | [ICD-11: 2A3Z] | Myelodysplastic syndrome | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Expression | CASP3 | hsa836 | |
Down-regulation | Expression | CCND1 | hsa595 | |
Down-regulation | Expression | Gli1 | hsa2735 | |
Down-regulation | Expression | PIK3CA | hsa5290 | |
Down-regulation | Expression | SMO | hsa6608 | |
In Vitro Model | MUTZ-1 | EBV-related Burkitt lymphoma | Homo sapiens (Human) | CVCL_1431 |
Result | The Smo inhibitor jervine and its combination with decitabine have a synergistic effect on the proliferation, cell cycle, and apoptosis of MUTZ-1 cells, and its mechanism may be achieved by interfering with the Shh signaling pathway. |
No. | Title | Href |
---|---|---|
1 | Synergistic inhibitory effect of Smo inhibitor jervine and its combination with decitabine can target Hedgehog signaling pathway to inhibit myelodysplastic syndrome cell line. Hematology. 2021 Dec;26(1):518-528. doi: 10.1080/16078454.2021.1950897. | Click |